PLN 33.9
(-4.24%)
Year | Net Debt | Net Debt Growth |
---|---|---|
2023 | -71.92 Million PLN | -12.24% |
2022 | -64.08 Million PLN | 41.62% |
2021 | -109.76 Million PLN | -6225.11% |
2020 | 1.79 Million PLN | 187.07% |
2019 | -2.05 Million PLN | -124.47% |
2018 | 8.4 Million PLN | 574.34% |
2017 | 1.24 Million PLN | 0.0% |
Year | Net Debt | Net Debt Growth |
---|---|---|
2024 Q2 | -50.17 Million PLN | 19.11% |
2024 Q1 | -62.01 Million PLN | 13.77% |
2023 Q3 | -33.92 Million PLN | 3.77% |
2023 Q2 | -35.25 Million PLN | 41.52% |
2023 FY | -71.92 Million PLN | -12.24% |
2023 Q4 | -71.92 Million PLN | -112.0% |
2023 Q1 | -60.28 Million PLN | 5.92% |
2022 Q1 | -103.66 Million PLN | 5.55% |
2022 Q4 | -64.08 Million PLN | 0.71% |
2022 FY | -64.08 Million PLN | 41.62% |
2022 Q3 | -64.54 Million PLN | 21.1% |
2022 Q2 | -81.8 Million PLN | 21.09% |
2021 Q2 | -128.22 Million PLN | -2360.72% |
2021 FY | -109.76 Million PLN | -6225.11% |
2021 Q1 | 5.67 Million PLN | 216.52% |
2021 Q4 | -109.76 Million PLN | 8.69% |
2021 Q3 | -120.2 Million PLN | 6.26% |
2020 FY | 1.79 Million PLN | 187.07% |
2020 Q2 | -5.27 Million PLN | 0.0% |
2020 Q4 | 1.79 Million PLN | 0.0% |
2019 FY | -2.05 Million PLN | -124.47% |
2019 Q4 | -2.05 Million PLN | 0.0% |
2018 FY | 8.4 Million PLN | 574.34% |
2017 FY | 1.24 Million PLN | 0.0% |
Name | Net Debt | Net Debt Difference |
---|---|---|
Bioceltix S.A. | -9.13 Million PLN | -687.348% |
BIOTON S.A. | 64.81 Million PLN | 210.98% |
Mabion S.A. | -11.98 Million PLN | -499.933% |
Molecure S.A. | -56.84 Million PLN | -26.522% |
NanoGroup S.A. | -537.61 Thousand PLN | -13278.794% |
Pharmena S.A. | -22.05 Million PLN | -226.106% |
Poltreg S.A. | -57.75 Million PLN | -24.532% |
Pure Biologics Spólka Akcyjna | 9.33 Million PLN | 870.746% |
Ryvu Therapeutics S.A. | -57.03 Million PLN | -26.113% |
Synthaverse S.A. | 67.86 Million PLN | 205.979% |
Urteste S.A. | -512 Thousand PLN | -13948.047% |